Yes. Harvard Pilgrim Health Care covers Spravato (esketamine) for treatment-resistant depression in Massachusetts when prior authorization criteria are met. Spravato is administered through HPHC's medical/specialty drug benefit; the medication itself requires prior authorization, while outpatient administration and observation do not require separate notification.
Harvard Pilgrim's published clinical Spravato PA criteria are administered through their provider portal and not publicly posted. HPHC's PA review SLA — "completed within two business days after receipt of medical information" (HPHC Provider Manual D.1, January 2026) — is HPHC's standard for all non-urgent prior authorizations and aligns with Massachusetts' state-level 211 CMR 52.07 "deemed granted" rule that applies to all MA commercial carriers. It is not a Spravato-specific differentiation.
Across Lumin Health's 2026 commercial Spravato (esketamine) authorizations: 100% approval rate, with a median 4-day decision turnaround. Lumin Health's pre-submission medical-necessity review and standardized clinical documentation packet contribute to this outcome. Individual approval depends on plan-specific PA criteria — see Harvard Pilgrim Health Care's policy summary below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
Harvard Pilgrim Health Care's commercial Spravato PA criteria are not publicly posted as a standalone document. The HPHC Provider Manual D.1 (January 2026) describes the general PA process, and HPHC's clinical Spravato criteria are administered through the CVS Health-Novologix Medical Drug Prior Authorization portal accessed via the HPHC provider portal.
HPHC generally follows the FDA's treatment-resistant depression definition for Spravato eligibility: at least one antidepressant from at least two different pharmacologic classes, at adequate dose for at least 8 weeks each, in the current depressive episode. Lumin Health verifies your specific HPHC plan's criteria during your consultation by submitting an eligibility check directly to HPHC.
What HPHC's published documents do confirm:
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine.
Massachusetts requires commercial insurers to cover mental health services on parity with medical/surgical benefits under Chapter 175 Section 47B and federal MHPAEA. This means Harvard Pilgrim Health Care cannot apply more restrictive prior authorization, visit limits, or cost-sharing to Spravato than to comparable medical treatments. For MassHealth members, Spravato coverage follows the MassHealth Drug List criteria, which differ from commercial; Lumin Health verifies your specific plan at consultation.
Two Massachusetts statutes are particularly relevant when a commercial insurer reviews a Spravato prior authorization:
The "deemed granted" rule. Under 211 CMR 52.07, a Massachusetts commercial carrier that fails to respond to a complete prior authorization request within two business days is deemed to have granted the authorization. This applies to all major Massachusetts commercial carriers — Aetna, Blue Cross Blue Shield of Massachusetts, Cigna, Harvard Pilgrim Health Care, Mass General Brigham Health Plan, UnitedHealthcare, and the Group Insurance Commission's contracted carriers.
External review through the Office of Patient Protection. If your commercial insurer denies a Spravato authorization, you have the right to request external review by the Health Policy Commission's Office of Patient Protection (OPP). The filing window is four months from the final internal denial; OPP issues decisions within 45 days. Historically, more than 40% of OPP external reviews resolve in the patient's favor — an unusually patient-favorable rate compared with most states' insurance-department-administered review processes.
Spravato treatment at Lumin Health is available at all four Massachusetts locations: Newton, Cambridge, Woburn, and Brookline. All Lumin Health Spravato locations are REMS-certified per FDA requirements.
How HPHC compares with other major Massachusetts commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes — HPHC requires PA for the Spravato medication under its medical benefit. Outpatient administration and observation services do not require separate PA notification.
HPHC's commercial Spravato clinical PA criteria are not publicly posted as a standalone document. HPHC generally follows the FDA's TRD definition: at least one antidepressant from at least two different pharmacologic classes, at adequate dose for at least 8 weeks each, in the current depressive episode. Lumin Health verifies your specific HPHC plan's criteria during your consultation.
HPHC's Provider Manual D.1 (January 2026) commits to a PA review "completed within two business days after receipt of medical information." This is HPHC's standard SLA for all non-urgent prior authorizations — not a Spravato-specific commitment — and it aligns with Massachusetts' state-level 211 CMR 52.07 "deemed granted" rule that applies to all MA commercial carriers. In Lumin Health's experience, complete HPHC submissions receive decisions within a few business days.
Lumin Health handles everything on your behalf so you don't have to worry. If your prior authorization is denied, our team manages the appeal process directly with Harvard Pilgrim — you don't need to navigate the paperwork or follow-ups. See the appeal section below for the full pathway, including external review through the Massachusetts Office of Patient Protection.
Yes — outpatient administration and observation are covered under the medical/behavioral benefit (administered by Optum Behavioral Health on behalf of HPHC) without requiring separate PA notification. Only the Spravato medication itself requires prior authorization under the HPHC medical benefit.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days from the date of service or the date Harvard Pilgrim denied payment for the service (per HPHC: "A request for an appeal must be submitted within 180 days of the date of service, or within 180 days from the date payment for a service is denied by Harvard Pilgrim. Appeals submitted beyond the 180-day time frame will not be accepted for review."). Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Harvard Pilgrim Health Care, Appeals & Grievances, P.O. Box 328, Canton, MA 02021. (Verify the exact mailing address on your specific Explanation of Benefits — commercial plans, Stride Medicare, and Part D each route to slightly different addresses.) For PA-stage clinical review, your prescriber can submit through HPHC's provider portal or the contact number listed on the denial letter.
Step 2 — Peer-to-peer (P2P) review. HPHC's commercial provider manual references peer-to-peer review at the prior-authorization denial stage. Your prescriber contacts the HPHC clinical reviewer named in the denial letter to request a P2P, typically before formal appeal submission.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), HPHC must resolve urgent internal appeals within 72 hours. Request by calling HPHC Member Services at the number on your ID card and documenting medical urgency.
Appeal levels. HPHC offers two internal appeal levels — and the Level 2 deadline is much shorter than Level 1. Per HPHC: "Second-level appeals must be received within 90 days of the date on the original appeal resolution letter." If Level 1 is denied, do not delay filing Level 2 — the 90-day clock starts the moment HPHC's Level 1 resolution letter is dated.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. HPHC's behavioral-health benefits are administered by Optum on certain commercial products (HPHC's parent Point32Health has multiple BH arrangements). Confirm the BH-vendor structure on your specific plan summary — this affects which appeal address applies. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Harvard Pilgrim Health Care medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days from the date of service or the date Harvard Pilgrim denied payment for the service (per HPHC: "A request for an appeal must be submitted within 180 days of the date of service, or within 180 days from the date payment for a service is denied by Harvard Pilgrim. Appeals submitted beyond the 180-day time frame will not be accepted for review."). Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Harvard Pilgrim Health Care, Appeals & Grievances, P.O. Box 328, Canton, MA 02021. (Verify the exact mailing address on your specific Explanation of Benefits — commercial plans, Stride Medicare, and Part D each route to slightly different addresses.) For PA-stage clinical review, your prescriber can submit through HPHC's provider portal or the contact number listed on the denial letter.
Step 2 — Peer-to-peer (P2P) review. HPHC's commercial provider manual references peer-to-peer review at the prior-authorization denial stage. Your prescriber contacts the HPHC clinical reviewer named in the denial letter to request a P2P, typically before formal appeal submission.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), HPHC must resolve urgent internal appeals within 72 hours. Request by calling HPHC Member Services at the number on your ID card and documenting medical urgency.
Appeal levels. HPHC offers two internal appeal levels — and the Level 2 deadline is much shorter than Level 1. Per HPHC: "Second-level appeals must be received within 90 days of the date on the original appeal resolution letter." If Level 1 is denied, do not delay filing Level 2 — the 90-day clock starts the moment HPHC's Level 1 resolution letter is dated.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. HPHC's behavioral-health benefits are administered by Optum on certain commercial products (HPHC's parent Point32Health has multiple BH arrangements). Confirm the BH-vendor structure on your specific plan summary — this affects which appeal address applies. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Harvard Pilgrim Health Care medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
